Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064948 | 1.00 | ALDH1A1 (0.41) | ALDH1A1KMT2ATDP1MEN1KDM4E | |
| SCHEMBL22604844 | 0.85 | MERTK (0.53) | ALDH1A1KMT2APIN1MERTKNPC1 | |
| SCHEMBL28702178 | 0.82 | PIN1 (0.57) | ALDH1A1KMT2ATDP1MEN1PIN1 | |
| SCHEMBL5217925 | 0.81 | MAOA (0.42) | ALDH1A1KMT2ATDP1MEN1TXNRD1 | |
| SCHEMBL22604807 | 0.80 | PIN1 (0.58) | ALDH1A1KMT2ATDP1MEN1PIN1 | |
| SCHEMBL9501122 | 0.77 | TDP1 (0.50) | ALDH1A1KMT2ATDP1MEN1KDM4E | |
| SCHEMBL22501504 | 0.76 | KMT2A (0.60) | ALDH1A1KMT2ATDP1MEN1KDM4E | |
| SCHEMBL1522100 | 0.76 | TDP1 (0.50) | ALDH1A1KMT2ATDP1MEN1KDM4E | |
| SCHEMBL2238161 | 0.76 | ALDH1A1 (0.38) | ALDH1A1KMT2ATDP1MEN1KDM4E | |
| SCHEMBL14475932 | 0.76 | NPC1 (0.38) | ALDH1A1KMT2ATDP1MEN1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-3908283-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-10125125-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-11-13 | — | — | US | disclosed |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-04-28 | — | — | US | disclosed |
| EP-2925743-B1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-02-03 | — | — | EP | disclosed |
| EP-1732562-B1 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1732562-B1 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070167473-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167473-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070078150-A1 | Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078150-A1 | Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078150-A1 | Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| EP-1732562-A2 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006083491-A2 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060155128-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078150-A1 | Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PC, GPR119, PNPO | ALDH1A1 269/4885KMT2A 2640/4885TDP1 2143/4885 |
| US-10125125-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | S100A9, S100B, S100A10 | ALDH1A1 4109/4885KMT2A 3107/4885TDP1 3192/4885 |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | ALDH1A1 4109/4885KMT2A 3107/4885TDP1 3192/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | ALDH1A1 3370/4885KMT2A 2081/4885TDP1 2926/4885 |
| US-20070167473-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PLPBP, PNPO, PDXK | ALDH1A1 238/4885KMT2A 2379/4885TDP1 2231/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 3370/4885KMT2A 2081/4885TDP1 2926/4885 |
| US-20060155128-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PNPO, PLPBP, FPGS | ALDH1A1 342/4885KMT2A 2143/4885TDP1 1780/4885 |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100A4, S100B | ALDH1A1 4370/4885KMT2A 4315/4885TDP1 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.